Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro- phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl] -amine (TG100435) and its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase

Drug Metabolism and Disposition

Volumn 35, Issue 12, 2007, Pages 2242-2251

  Kousba, Ahmed ^a   Soll, Richard ^a   Yee, Shiyin ^a   Martin, Michael ^a  

^a TargeGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; [7 (2,6 DICHLOROPHENYL) 5 METHYLBENZO[1,2,4]TRIAZIN 3 YL][4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL]AMINE; CYTOCHROME P450 REDUCTASE; DEXTROMETHORPHAN; DEXTRORPHAN; DIMETHYLANILINE MONOOXYGENASE; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; PARACETAMOL; PHENACETIN; PROTEIN TYROSINE KINASE INHIBITOR; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TG 100435; TG 100855; THIAMAZOLE; TOLBUTAMIDE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ENZYME STABILITY; HUMANS; KETOCONAZOLE; KINETICS; METHIMAZOLE; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; OXYGENASES; PROTEIN KINASE INHIBITORS; PYRROLIDINES; RECOMBINANT PROTEINS; SRC-FAMILY KINASES; TEMPERATURE; TRIAZINES;

EID: 36348967194     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017384     Document Type: Article

References (36)

1. Bayliss MK, Bell JA, Jenner WN, Park GR, and Wilson K (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29:253-268.
2. Carmella SG, Borukhova A, Akerkar SA, and Hecht SS (1997) Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone, a tobacco-specific lung carcinogen. Cancer Epidemiol Biomarkers Prev 6:113-120.
3. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
4. Cashman JR and Zhang J (2006) Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65-100.
5. Dudka J (2006) Decrease in NADPH-cytochrome P450 reductase activity of the human heart, liver and lungs in the presence of alpha-lipoic acid. Ann Nutr Metab 50:121-125.
6. Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, Szumilo J, Tokarska E, Klepacz R, and Murias M (2005) Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol 97:74-79.
7. Grothusen A, Hardt J, Brautigam L, Lang D, and Bocker R (1996) A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monoxygenases in human liver microsomes. Arch Toxicol 71:64-71.
8. Haining RL, Hunter AP, Sadeque AJ, Philpot RM, and Rettie AE (1997) Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. Drug Metab Dispos 25:790-797.
9. Hines RN, Cashman JR, Philpot RM, Williams DE, and Ziegler DM (1994) The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol Appl Pharmacol 125:1-6.
10. Hu SX, Soll R, Yee S, Lohse DL, Kousba A, Zeng B, Yu X, McPherson A, Renick J, Cao J, et al. (2007) Metabolism and pharmacokinetics of a novel Src inhibitor TG100435 and its active N-oxide metabolite TG100855. Drug Metab Dispos 35:929-936.
11. Lin J and Cashman J (1997) N-Oxygenation of phenethylamine to the trans-oxime by adult human liver flavin-containing monooxygenase and retroreduction of phenethylamine hydroxylamine by human liver microsomes. J Pharmacol Exp Ther 282:1269-1279.
12. Kedderis GL and Rickert DE (1985) Loss of rat liver microsomal cytochrome P-450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab Dispos 13:58-61.
13. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human flavin-containing monooxygenases 1 (FMO1) and 3 developmental expression. Pediatr Res 51:236-243.
14. Krieter PA, Ziegler DM, Hill KE, and Burk RF (1984) Increased biliary GSSG efflux from rat liver perfused with thiocarbamamide substrate for the flavin-containing monooxygenases. Mol Pharmacol 26:122-127.
15. Krueger SK, Vandyke JE, Williams DE, and Hines RN (2006) The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab Rev 38:139-147.
16. McManus ME, Stupans I, Burgess W, Koenig JA, de la Hall PM, and Birkett DJ (1987) Flavin-containing monooxygenase activity in human liver microsomes. Drug Metab Dispos 15:256-261.
17. Newton DJ, Wang RW, and Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
18. Noronha G, Barrett K, Boccia A, Brodhag T, Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, et al. (2007) Discovery of [7-(2,6-dichlorophenyl)- 5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)phenyl] amine a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett 17:602-608.
19. Obach R (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
20. Ortiz de Montellano PR, Mathews JM, and Langry KC (1984) Autocatalytic inactivation of cytochrome P-450 and chloroperoxidase by l-aminobenzotriazole and other aryne precursors. Tetrahedron 40:511-519.
21. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, and Philpot RM (1995) Characterization of flavin containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit orthologs. Arch Biochem Biophys 317:275-284.
22. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
23. Parte P and Kupfer D (2005) Oxidation of tamoxifen by human flavin containing monooxygenases (FMO1) and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochrome P450 and hemoglobin. Drug Metab Dispos 33:1446-1452.
24. Pirmohamed M, Willams D, Madden S, Templeton E, and Park K (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990.
25. Rawden HC, Kokwaro GO, Ward SA, and Edwards G (2000) Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49:313-322.
26. Rettie AE, Meier GP, and Sadeque AJM (1995) Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 96:3-15.
27. Ring BJ, Wrighton SA, Aldridge SLK, Hansen K, Haehner B, and Shipley LA (1999) Flavin-containing monooxygenase-mediated N-oxidation of the M1-muscarinic agonist xanomeline. Drug Metab Dispos 27:1099-1103.
28. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
29. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, and Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30:327-343.
30. Stormer E, Roots I, and Brockmoller J (2000) Benzydamine N-oxygenation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J. Clin Pharmacol 50:553-561.
31. Summy JM and Gallick GE (2006) Treatment for advanced tumors: Src reclaims center stage. Clin Cancer Res 12:1398-1401.
32. Trevino JG, Summy JM, and Gallick GE (2006) SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6:681-687.
33. Tugnait M, Hawes EM, Mckay G, Rettie AE, Haining RL, and Midha KK (1997) N-Oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 25:524-527.
34. Walsky L and Obach S (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
35. Yeung CK, Lang DH, Thummel KE, and Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney and intestine. Drug Metab Dispos 28:1107-1111.
36. Ziegler DM (1990) Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci 11:321-324.